The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...

Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...

FLAMeS, a new convolutional neural network, enhances MS lesion segmentation accuracy using only T2-weighted FLAIR images, ...

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...

Panelists discuss how relapse is one of the most significant challenges in schizophrenia management, often resulting in ...

Panelists discuss how schizophrenia typically evolves through distinct phases—from first-episode psychosis to chronic illness ...

These top 5 stories underscore how 2025 was a year of constant friction at the intersection of public health and political ...

Panelists discuss how defining and tracking meaningful real-world outcomes ensures accountability and value in MASH ...

From there, the discussion turns to bispecific antibodies for relapsed/refractory multiple myeloma (RRMM) and the unmet needs ...

We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...

Blinatumomab addition to chemotherapy significantly improves survival and reduces relapse in pediatric B-cell acute ...